The St. Jude Promesa y Esperanza® (Promise and Hope), an initiative by St. Jude Children’s Research Hospital® and Univision Radio, the leading radio network serving Hispanic America, partner to increase awareness for national fundraiser against childhood cancer. As part of this partnership, Univision Radio will broadcast special programming on February 10 and 11 asking listeners to become Angeles de Esperanza (Angels of Hope) by making a donation of $20 per month, to find cures and save children.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65476-univision-radio-st-jude-children-s-research-hospital-national-fundraiser
Having lost his mother to the disease, singer, songwriter Gavin DeGraw knows firsthand how devastating pancreatic cancer is for patients and their families. Gavin is turning his grief into action by helping the Lustgarten Foundation raise awareness by encouraging people to get involved with the Foundation.
“My mother didn’t make it and unfortunately right now that’s a common story. But it doesn’t have to be the story permanently,” DeGraw said. “By funding research, the Lustgarten Foundation is going to change the course of this disease. I encourage everyone to get involved in some way – join a walk or make a donation.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213753-lustgarten-foundation-pancreatic-cancer-awareness/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
The Celiac Disease Center at Columbia University, the premier center for celiac disease research and treatment, unveiled the I Didn’t Know video campaign, offering an inside look at the serious impact of celiac disease on patients at the 13th Anniversary gala on November 13th in New York City. The series chronicles the lives of several patients experiencing a wide range of debilitating symptoms associated with undiagnosed celiac disease, including an inability to walk, developmental delays, multiple miscarriages and infertility.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7322351-celiac-disease-center-at-columbia-university-public-service-announcements-and-gala/
LIFEWTR, the premium water brand that believes art is as essential to life as water, is committing to advancing arts education in schools nationwide as the foundation of where creativity begins. New research shows we are heading toward a creativity crisis in schools – 91% of American parents agree that arts education is important to teach children to think outside the box, yet 4 in 5 people say that arts education is not being offered as much as it once wasi. This week, in partnership with Americans for the Arts during its National Arts Action Summit, LIFEWTR announced its commitment to making every day vibrant by infusing creativity into schools across the U.S., reaching 10 million students through school and community beautification projects and arts education programming as part of its continued collaboration with Scholastic.
“At LIFEWTR we believe that arts education plays an invaluable role in helping students achieve success and reach their full potential in school and beyond,” said Alexis Porter, Senior Director, LIFEWTR Marketing. “Students involved in the arts are four times more likely to be recognized for academic achievementii, which is why it’s more important than ever to #BringArtBackToSchools. Through our collaboration with Scholastic and Americans for the Arts, we are making a concerted effort to impact 10 million students nationwide through arts education programming and to preserve the critical source of where creativity begins, in our schools.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8503551-pepsico-lifewtr-scholastic-macklemore-school-art-beautification-project/
Christina Nicols, senior vice president and director of strategic planning and research at Hager Sharp, was named the Washington Women in Public Relations’ (WWPR) 2015 Washington PR Woman of the Year Friday in a ceremony honoring top public relations executives and celebrating women in communications.
Nicols was one of three public relations professionals chosen as an honoree for the 26th annual award. The other finalists were Carrie Fox, president of C. Fox Communications, and Lisa Throckmorton, chief operations officer at SpeakerBox Communications. The three finalists represent women who have led some of the most influential communications campaigns in the District and across the country.
“This is a phenomenal honor and I am humbled to be surrounded by such exemplary leaders in the field who are dedicated to mentoring and supporting the next generation of public relations professionals,” said Nicols. “It is a special privilege to join the ranks of previous PR Woman of the Year recipients including Hager Sharp’s own cofounders Susan Hager and Marcia Sharp, as well as our CEO Jennifer Wayman and executive vice president Debra Silimeo.”
Nicols was presented the award by Silimeo, the 2010 PR Woman of the Year, at Friday’s luncheon.
To view the multimedia release go to:
http://www.multivu.com/players/English/7695751-2015-wwpr-woman-of-the-year-award/
Anyone who has seen the blockbuster movies The Thomas Crown Affair or Bullitt will want to read The Pursuit of Happiness, a new novel by the same writer, Alan Trustman. The highest paid screenwriter in Hollywood at one time, Trustman now turns his pen to fiction, which reads and moves with the same crime thriller speed as his movies.
From the opening chapter we are rocketed into the world of a Boston bad boy who is recruited to work for the government.
“All of the material in The Pursuit of Happiness is true,” says Trustman. “Not a lot of people know that Boston was the contract killing capitol of the country throughout the 1940s – 1970s. Maybe later. I did a lot of research on the Boston gang wars.”
Media Contact: For a review copy of Silver Dollar or to arrange an interview with Alan Trustman, contact Scott Lorenz of Westwind Communications Book Marketing at scottlorenz@westwindcos.com or by phone at 734-667-2090 http://www.book-marketing-expert.com Thriller
GB Sciences, Inc. (OTCQB: GBLX) announces the success of its first annual, “Innovation in Medical Cannabis Therapies” (IMCT) Symposium, held on Friday, November 9th at the “Keep Memory Alive” Event Center at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Throughout the day’s program, there was an emerging sense of heightened responsibility on the part of the cannabis industry to better address medical cannabis patients' needs through research and development of medical cannabis products that are better standardized, more easily-dosed, and made more widely-available to cannabis patients at a fair price.
To view the multimedia release go to:
https://www.multivu.com/players/English/8308958-gb-sciences-2018-medical-cannabis-therapies-symposium/
Online Registration Guidline
ACRI is specialized in providing Clinical Research Courses like Pg Diploma in clinical CDM and SAS course with guarantee internship in leading CRO’S & 100% Placement.
Reach us at:
Avigna Clinical Research Institute:-
No.33,3rd Floor,15th Cross,
2nd Phase,J.P.Nagar,100ft Ring Road,
Bangalore-560078
080-26588910 / 91-9741600499
http://www.acriindia.com
info@acriindia.com
As an addition to the social responsibility project it started for sheltering street animals, the lucky address for shopping, n11.com, has now redesigned its delivery boxes, turning them into portable "homes" that can protect animals living on the streets from the harsh conditions of winter.
Contributing to the e-trade sector with its innovative activities, n11.com has completed the design work that it has been conducting in the last period, turning its delivery boxes into portable "homes" for street animals.
The special boxes were designed to especially endure cold weather conditions and were produced after approximately a year of Research and Development efforts. From now on, shoppers who order pet food on n11.com will be contributing to providing street dogs and cats with a warm home.
To view the multimedia release go to:
http://www.multivu.com/players/English/7664151-n11-com-boxes-homes-animals/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
MONROE, La., Feb. 28, 2019 – Furthering its dedication to helping protect the internet from malicious actors, CenturyLink, Inc. (NYSE:CTL) is sharing intelligence on the Necurs botnet uncovered by its new threat research and operations division, Black Lotus Labs.
The mission of Black Lotus Labs is to leverage CenturyLink’s network visibility to help protect customers and keep the internet clean. Among the ways Black Lotus Labs does this is by tracking and disrupting botnets like Necurs, a prolific and globally dispersed spam and malware distribution botnet which has recently demonstrated a hiding technique to both avoid detection and quietly amass more bots.
To view the multimedia release go to:
https://www.multivu.com/players/English/8238355-centurylink-black-lotus-labs/
